Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ureteral Neoplasms | 4 | 2022 | 228 | 1.450 |
Why?
|
| Kidney Neoplasms | 12 | 2021 | 3022 | 1.430 |
Why?
|
| Nephrectomy | 9 | 2019 | 779 | 1.280 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2017 | 2326 | 1.170 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2012 | 181 | 0.850 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2022 | 962 | 0.750 |
Why?
|
| Prostate | 3 | 2024 | 1088 | 0.730 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2021 | 43 | 0.570 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2022 | 2341 | 0.520 |
Why?
|
| Penile Induration | 2 | 2012 | 26 | 0.510 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2015 | 59 | 0.510 |
Why?
|
| Penis | 2 | 2012 | 123 | 0.500 |
Why?
|
| Nomograms | 1 | 2015 | 313 | 0.450 |
Why?
|
| Patient Admission | 1 | 2012 | 220 | 0.390 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 126 | 0.390 |
Why?
|
| Penile Neoplasms | 2 | 2024 | 161 | 0.380 |
Why?
|
| Ureter | 1 | 2012 | 209 | 0.370 |
Why?
|
| Testicular Neoplasms | 4 | 2016 | 529 | 0.360 |
Why?
|
| Global Health | 1 | 2014 | 657 | 0.350 |
Why?
|
| Bacterial Infections | 1 | 2012 | 479 | 0.330 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2014 | 328 | 0.280 |
Why?
|
| Carcinoma | 2 | 2020 | 2578 | 0.270 |
Why?
|
| Retrospective Studies | 16 | 2024 | 37905 | 0.230 |
Why?
|
| Metastasectomy | 2 | 2016 | 200 | 0.230 |
Why?
|
| Mitomycin | 2 | 2022 | 208 | 0.220 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2022 | 55 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 602 | 0.190 |
Why?
|
| Biopsy | 3 | 2012 | 3443 | 0.180 |
Why?
|
| Male | 24 | 2024 | 123000 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6207 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 2992 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2021 | 277 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2020 | 327 | 0.170 |
Why?
|
| Urothelium | 1 | 2020 | 254 | 0.160 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 10001 | 0.160 |
Why?
|
| Kidney | 2 | 2019 | 2146 | 0.150 |
Why?
|
| Humans | 29 | 2024 | 261506 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 481 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5542 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 4975 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 726 | 0.140 |
Why?
|
| Adrenal Glands | 1 | 2015 | 122 | 0.130 |
Why?
|
| Sarcoma | 2 | 2016 | 1725 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 96 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2019 | 769 | 0.120 |
Why?
|
| Middle Aged | 13 | 2021 | 86204 | 0.120 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2013 | 17 | 0.120 |
Why?
|
| Laparoscopy | 2 | 2013 | 1225 | 0.120 |
Why?
|
| Urinary Catheterization | 1 | 2013 | 117 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 4988 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 11538 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2015 | 262 | 0.110 |
Why?
|
| Ureteroscopy | 1 | 2012 | 46 | 0.110 |
Why?
|
| Penile Erection | 1 | 2012 | 86 | 0.110 |
Why?
|
| Aged | 10 | 2021 | 70117 | 0.110 |
Why?
|
| Prostatic Diseases | 1 | 2012 | 30 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 206 | 0.110 |
Why?
|
| Electroporation | 1 | 2013 | 126 | 0.110 |
Why?
|
| Penile Prosthesis | 1 | 2012 | 28 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 5767 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2013 | 148 | 0.100 |
Why?
|
| Bacteriuria | 1 | 2012 | 77 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 945 | 0.100 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 212 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 10035 | 0.090 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.090 |
Why?
|
| Female | 11 | 2020 | 141928 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2021 | 12873 | 0.080 |
Why?
|
| Adult | 10 | 2020 | 77950 | 0.080 |
Why?
|
| Endosonography | 1 | 2012 | 536 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 429 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2015 | 6869 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 3890 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 5112 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 446 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 915 | 0.070 |
Why?
|
| Survival Rate | 3 | 2016 | 12221 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2021 | 32848 | 0.060 |
Why?
|
| Inguinal Canal | 1 | 2024 | 60 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 29902 | 0.060 |
Why?
|
| Prognosis | 3 | 2015 | 21713 | 0.060 |
Why?
|
| Nephroureterectomy | 1 | 2022 | 39 | 0.050 |
Why?
|
| Hospitalization | 1 | 2011 | 2083 | 0.050 |
Why?
|
| Texas | 3 | 2021 | 6311 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2007 | 620 | 0.050 |
Why?
|
| Aggression | 1 | 2024 | 252 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 310 | 0.050 |
Why?
|
| Israel | 1 | 2020 | 53 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2020 | 70 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 14889 | 0.050 |
Why?
|
| Overweight | 1 | 2024 | 484 | 0.050 |
Why?
|
| Risk Factors | 4 | 2021 | 17523 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.040 |
Why?
|
| Hydrogels | 1 | 2020 | 123 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7551 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 217 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2024 | 962 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 403 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 13658 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3981 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2024 | 1959 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2024 | 2203 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1742 | 0.030 |
Why?
|
| Young Adult | 4 | 2016 | 21445 | 0.030 |
Why?
|
| Cisplatin | 1 | 2022 | 2432 | 0.030 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2024 | 2967 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2014 | 217 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2884 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1054 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 665 | 0.020 |
Why?
|
| Reoperation | 1 | 2015 | 1382 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2012 | 319 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 899 | 0.020 |
Why?
|
| Swine | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4298 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 2803 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 192 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 4844 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 960 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 6682 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 9180 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Child | 2 | 2014 | 29154 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 5687 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 13310 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 16273 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 59536 | 0.000 |
Why?
|